CHABiotech CO., Ltd   Report issue

For profit Phase 1 Phase 2
Founded: Seongnam Korea, Republic of (2000)

Organization Overview

First Clinical Trial
2012
NCT01674829
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

CHABiotech CO., Ltd

Active Ingredients

Drugs in Phase 2 Trials (4)

cb-ac-02 (1 trial)

cordstem-dd (1 trial)

ma09-hrpe (2 trials)

umbilical cord mesenchymal stem cells (1 trial)

Drugs in Phase 1 Trials (1)

cbt101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Back Pain (Phase 2)

Cerebral Infarction (Phase 2)

Infarction (Phase 2)

Low Back Pain (Phase 2)

Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 5